163 related articles for article (PubMed ID: 12009284)
1. Virosome-mediated delivery of protein antigens to dendritic cells.
Bungener L; Serre K; Bijl L; Leserman L; Wilschut J; Daemen T; Machy P
Vaccine; 2002 May; 20(17-18):2287-95. PubMed ID: 12009284
[TBL] [Abstract][Full Text] [Related]
2. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs.
Bungener L; Huckriede A; Wilschut J; Daemen T
Biosci Rep; 2002 Apr; 22(2):323-38. PubMed ID: 12428908
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone inhibits the antigen presentation of dendritic cells in MHC class II pathway.
Pan J; Ju D; Wang Q; Zhang M; Xia D; Zhang L; Yu H; Cao X
Immunol Lett; 2001 Apr; 76(3):153-61. PubMed ID: 11306142
[TBL] [Abstract][Full Text] [Related]
4. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T
Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665
[TBL] [Abstract][Full Text] [Related]
5. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
6. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms.
Askew D; Chu RS; Krieg AM; Harding CV
J Immunol; 2000 Dec; 165(12):6889-95. PubMed ID: 11120813
[TBL] [Abstract][Full Text] [Related]
7. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway.
Nakanishi T; Hayashi A; Kunisawa J; Tsutsumi Y; Tanaka K; Yashiro-Ohtani Y; Nakanishi M; Fujiwara H; Hamaoka T; Mayumi T
Eur J Immunol; 2000 Jun; 30(6):1740-7. PubMed ID: 10898512
[TBL] [Abstract][Full Text] [Related]
8. Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.
Miura N; Akita H; Tateshita N; Nakamura T; Harashima H
Mol Ther; 2017 Apr; 25(4):1003-1013. PubMed ID: 28236573
[TBL] [Abstract][Full Text] [Related]
9. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
Herrera OB; Brett S; Lechler RI
Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
[TBL] [Abstract][Full Text] [Related]
10. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function.
Peng X; Hussain SF; Paterson Y
J Immunol; 2004 May; 172(10):6030-8. PubMed ID: 15128786
[TBL] [Abstract][Full Text] [Related]
11. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
Adams EW; Ratner DM; Seeberger PH; Hacohen N
Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
[TBL] [Abstract][Full Text] [Related]
12. Hantavirus infection of dendritic cells.
Raftery MJ; Kraus AA; Ulrich R; Krüger DH; Schönrich G
J Virol; 2002 Nov; 76(21):10724-33. PubMed ID: 12368315
[TBL] [Abstract][Full Text] [Related]
13. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA.
Chan K; Lee DJ; Schubert A; Tang CM; Crain B; Schoenberger SP; Corr M
J Immunol; 2001 Mar; 166(5):3061-6. PubMed ID: 11207256
[TBL] [Abstract][Full Text] [Related]
14. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
15. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats.
Chaux P; Favre N; Martin M; Martin F
Int J Cancer; 1997 Aug; 72(4):619-24. PubMed ID: 9259401
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells.
Mitchell DA; Nair SK; Gilboa E
Eur J Immunol; 1998 Jun; 28(6):1923-33. PubMed ID: 9645374
[TBL] [Abstract][Full Text] [Related]
18. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells.
Moffat JM; Cheong WS; Villadangos JA; Mintern JD; Netter HJ
Vaccine; 2013 Apr; 31(18):2310-6. PubMed ID: 23473776
[TBL] [Abstract][Full Text] [Related]
20. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity.
Watanabe S; Kagamu H; Yoshizawa H; Fujita N; Tanaka H; Tanaka J; Gejyo F
J Immunol; 2003 Dec; 171(11):5828-36. PubMed ID: 14634092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
